Serum vascular endothelial growth factor and angiogenesis are related to the prognosis of patients with gastrointestinal stromal tumors

Irish Journal of Medical Science

Volumn 178, Issue 3, 2009, Pages 315-320

  Wang, T B ^a   Qiu, W S ^a   Wei, B ^a   Deng, M H ^a   Wei, H B ^a   Dong, W G ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

GIST; MVD; Survival; SVEGF; VEGF

Indexed keywords

CD31 ANTIGEN; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MITOSIS; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR VOLUME; BIOSYNTHESIS; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; DISEASE COURSE; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; STATISTICS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MICROVESSELS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; STATISTICS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; KAPLAN-MEIER ESTIMATE;

EID: 77249122617     PISSN: 00211265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11845-009-0315-7     Document Type: Article

References (33)

1. Antonescu CR, Viale A, Sarran L et al (2004) Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 10(10):3282-3290. doi: 10.1158/1078-0432.CCR-03-0715 (Pubitemid 38685432)
2. Chen WZ, Huang CJ, Wu MT et al (2005) Hypoxia-inducible factor-1a is associated with risk of aggressive behavior and tumor angiogenesis in gastrointestinal stromal tumor. Jpn J Clin Oncol 35(4):207-213. doi:10.1093/jjco/hyi067 (Pubitemid 40796855)
3. Demetri GD, Von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in adVanced gastrointestinal stromal tumors. N Engl J Med 347(7):472-480. doi:10.1056/ NEJMoa020461
4. Joensuu H, Fletcher C, Dimitrijevic S et al (2002) Management of malignant gastrointestinalstromal tumours. Lancet Oncol 3:655-664. doi:10.1016/S1470-2045(02)00899-9 (Pubitemid 35314908)
5. Song ZJ, Gong P, Wu YE (2002) Relationship between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer. World J Gastroenterol 8:591-595
6. Zhang H, Wu J, Meng L et al (2002) Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells. World J Gastroenterol 8(6):994-998
7. Djordjevic G, Mozetic V, Mozetic DV et al (2007) Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma. Pathol Res Pract 203(2):99-106. doi:10.1016/j.prp.2006.12.002 (Pubitemid 46173164)
8. Des Guetz G, Uzzan B, Nicolas P et al (2006) Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 94(12):1823-1832. doi:10.1038/sj.bjc.6603176 (Pubitemid 43882572)
9. Guo J, Higashi K, Ueda Y et al (2006) Microvessel density: correlation with 18F-FDG uptake and prognostic impact in lung adenocarcinomas. J Nucl Med 47(3):419-425
10. Ilhan N, Ilhan N, Ilhan Y et al (2004) C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer. World J Gastroenterol 10(8):1115-1120
11. Famulski W, Sulkowska M, Wincewicz A et al (2006) P53 correlates positively with VEGF in preoperative sera of colorectal cancer patients. Neoplasma 53(1):43-48
12. Cressey R, Wattananupong O, Lertprasertsuke N et al (2005) Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis. BMC Cancer 5:128. doi:10.1186/1471- 2407-5-128
13. Roumen RM, Slooter GD, Croiset Van Uchelen FA et al (2005) Preoperative serum vascular endothelial growth factor is not a marker for subsequent recurrence during long-term follow-up of colorectal cancer patients. Dis Colon Rectum 48(5):1070-1075. doi:10.1007/s10350-004-0870-y (Pubitemid 40884199)
14. Arita S, Kikkawa F, Kajiyama H et al (2005) Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma. Int J Gynecol Cancer 15(2):329-336. doi: 10.1111/j.1525-1438.2005.15225.x (Pubitemid 40396974)
15. Poncelet C, Fauvet R, Feldmann G et al (2004) Prognostic value of Von Willebrand factor, CD34, CD31, and vascular endothelial growth factor expression in women with uterine leiomyosarcomas. J Surg Oncol 86(2):84-90. doi:10.1002/jso.20055 (Pubitemid 38580519)
16. Potti A, Ganti AK, Tendulkar K et al (2004) Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. J Cancer Res Clin Oncol 130(1):52-56. doi:10.1007/ s00432-003-0504-510 (Pubitemid 38161248)
17. Hong T, Shimada Y, Uchida S et al (2001) Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma. Int J Mol Med 8(2):141-148
18. Nakayama T, Cho YC, Mine Y et al (2006) Expression of vascular endothelial growth factor and its receptors VEGFR-1 and 2 in gastrointestinal stromal tumors, leiomyomas and schwannomas. World J Gastroenterol 12(38):6182-6187
19. Jin T, Nakatani H, Taguchi T et al (2006) STI571 (Gleevec) suppresses the expression of vascular endothelial growth factor in the gastrointestinal stromal tumor cell line, GIST-T1. World J Gastroenterol 12:703-708
20. Takahashi R, Tanaka S, Kitadai Y et al (2003) Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 64:266-274. doi: 10.1159/000069316 (Pubitemid 36438812)
21. Imamura M, Yamamoto H, Nakamura N et al (2007) Prognostic significance of angiogenesis in gastrointestinal stromal tumor. Mod Pathol 20:529-537. doi:10.1038/modpathol.3800767 (Pubitemid 46631995)
22. Takahashi R, Tanaka S, Hiyama T et al (2003) Hypoxia-inducible factor-1alpha expression and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncol Rep 10(4):797-802
23. De Giorgi U, Aliberti C, Benea G et al (2005) Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 11(17):6171-6176. doi:10.1158/1078-0432.CCR- 04-2046 (Pubitemid 41262944)
24. McAuliffe JC, Lazar AJ, Yang D et al (2007) Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. Clin Cancer Res 13(22 Pt 1):6727-6734. doi:10.1158/1078-0432.CCR-07-0895 (Pubitemid 350206810)
25. Mangia A, Chiriatti A, Ranieri G et al (2006) H pylori status and angiogenesis factors in human gastric carcinoma. World J Gastroenterol 12(34):5465-5472
26. Cressey R, Wattananupong O, Lertprasertsuke N et al (2005) Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis. BMC Cancer 5:128. doi:10.1186/1471- 2407-5-128
27. Celen O, Kahraman I, Yildirim E et al (2004) Correlation of vascular endothelial growth factor (VEGF) and CEA with clinicopathological variables in colorectal cancer patients. Neoplasma 51(4):293-299
28. De Vita F, Orditura M, Lieto E et al (2004) Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 100(2):270-278. doi:10.1002/cncr.11911 (Pubitemid 38063634)
29. Akbulut H, Altuntas F, Akbulut KG et al (2002) Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma. Cytokine 20(4):184-190. doi:10.1006/cyto.2002.1993 (Pubitemid 37163470)
30. Kumar H, Heer K, Duthie GS et al (2002) Kinetics of postoperative serum vascular endothelial growth factor (VEGF)-can it be used to predict curative resections in colorectal cancer? Anticancer Res 22(6B):3717-3722
31. Yoon SS, Segal NH, Olshen AB et al (2004) Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Ann Oncol 15(8):1261-1266. doi:10.1093/annonc/mdh309 (Pubitemid 39199315)
32. Bono P, Krause A, Von Mehren M et al (2004) Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood 103:2929-2935. doi:10.1182/blood- 2003-10-3443
33. Norden-Zfoni A, Desai J, Manola J et al (2007) Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 13(9):2643-2650. doi:10.1158/1078-0432.CCR- 06-0919 (Pubitemid 46788031)